Last reviewed · How we verify
Lipofundin
At a glance
| Generic name | Lipofundin |
|---|---|
| Sponsor | Shanghai Jiao Tong University School of Medicine |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Role of Intralipid in Management of Organophosphorus Poisoning (PHASE2, PHASE3)
- The HOME Study (HPN With OMEGA-3) (PHASE4)
- Anakinra vs. Steroids for the Treatment of Gout Attacks in Patients With Renal Disease (ASGARD): A Feasibility Study (PHASE2, PHASE3)
- Comparison of Two Different Lipid Emulsions for Parenteral Nutrition in Preterm Infants (PHASE2)
- Impact of Fish Oil-enriched Lipid Emulsion on Fatty Acid and Inflammatory Response in Infants After Surgery (NA)
- Lipid Emulsions and Liver Function - Results After 5 Years. (PHASE4)
- Effects of Fat Emulsions on PNALD and Oxidative Stress in Premature Infants (PHASE4)
- Reduction of Neonatal Parenteral Nutrition Associated Cholestasis Through Lipid Emulsions (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lipofundin CI brief — competitive landscape report
- Lipofundin updates RSS · CI watch RSS
- Shanghai Jiao Tong University School of Medicine portfolio CI